III.J.29. Advanced
Anticonvulsant. By FY97, demonstrate safety and efficacy
sufficient for a Milestone 0 transition of an advanced
anticonvulsant adjunct or component for the soldier/buddy-use
nerve agent antidote. Advanced anticonvulsant will overcome
deficiencies of current anticonvulsant, Convulsant Antidote
for Nerve Agent (CANA); i.e., will be more effective in
stopping ongoing convulsive seizures, preventing their
recurrence, and protecting against nerve-agent-induced,
seizure-related brain damage. It will also demonstrate less
abuse potential than CANA. Achieve Milestone 1 transition by
FY99.